BioPharma Dive1 min read
saveWith FDA nod, Regeneron brings an RNAi drug to autoimmune disease
The product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.
comments(0)
5-min edit window · permanent after that